
CLAIMS

What is claimed:

1. A compound represented by Formula (I):



(I)

,

or a pharmaceutically acceptable salt thereof, wherein:

R_1 is selected from the group consisting of:

1) Hydrogen;
2) Halogen;
3) CN;
4) optionally substituted -C_1-C_8 alkyl; and
5) optionally substituted -C_1-C_8 alkyl–O-R_{11};

R_2 and R_5 are each independently selected from the group consisting of:

1) Hydrogen; and
2) optionally substituted -C_1-C_8 alkyl;

A is optionally substituted aryl or optionally substituted heteroaryl;

R_3 is optionally substituted aryl or optionally substituted heteroaryl;

R_4 is selected from the group consisting of:

1) optionally substituted -C_3-C_{12} cycloalkyl;
2) optionally substituted -C_3-C_{12} cycloalkenyl;
3) optionally substituted 3- to 12-membered heterocyclyl;
4) optionally substituted aryl;
5) optionally substituted heteroaryl;
6) optionally substituted aryl-O-;
7) optionally substituted heteroaryl-O;
8) optionally substituted aryl-C_1-C_4-alkyl; and
9) optionally substituted heteroaryl-C_1-C_4-alkyl;


each R_6 is the same or different and independently selected from hydrogen, halogen, hydroxyl, protected hydroxyl, cyano, amino, protected amino, nitro, optionally substituted -C_1-C_8 alkyl, optionally substituted -C_1-C_8 alkoxy, optionally substituted -NHC_1-C_8 alkyl, optionally substituted -S-(-C_1-C_8 alkyl), optionally substituted -SO_2-(-C_1-C_8 alkyl), - optionally substituted -SO_2-NH-(-C_1-C_8 alkyl), optionally substituted -NH-SO_2-(-C_1-C_8 alkyl), -CO_2R_{12} , –$NR_{13}R_{14}$, and -CO-$NR_{13}R_{14}$;

R_{11} and R_{12} are each independently is selected from the group consisting of:

1) optionally substituted -C_1-C_8 alkyl;
2) optionally substituted -C_2-C_8 alkenyl;
3) optionally substituted -C_2-C_8 alkynyl;
4) optionally substituted -C_3-C_8 cycloalkyl;
5) optionally substituted -C_3-C_8 cycloalkenyl;
6) optionally substituted 3- to 8-membered heterocycloalkyl;
7) optionally substituted aryl; and
8) optionally substituted heteroaryl;

R_{13} and R_{14} are each independently selected from hydrogen, optionally substituted –C_1-C_8-alkyl, optionally substituted –C_2-C_8-alkenyl, optionally substituted –C_2-C_8-alkynyl; optionally substituted –C_3-C_8-cycloalkyl, -C(O)R_{12}, -$S(O)_2R_{12}$, and -$S(O)_2NHR_{12}$, and optionally substituted – C_1-C_8-alkoxy; alternatively, R_{13} and R_{14} are taken together with the nitrogen they attached to form a heterocyclic ring; and n is 0, 1, 2, 3 or 4.


2. The compound of claim 1, represented by Formula (Ib),



(Ib)


or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1, wherein A is selected from one of the following by removal of two hydrogen atoms:



wherein each of the above shown is optionally substituted when possible.

4. The compound of claim 1, wherein R_4 is selected from one of the following by removal of one hydrogen atom:




wherein each of the above shown is optionally substituted when possible.

5. The compound of claim 1, wherein R_4 is substituted by one, two or three of the following substituents:

halo, $-CH_3$, $-CF_3$, $-OCF_3$, -CN, $-NH_2$, -OH, $-CH_2N(CH_3)_2$, $-C(O)CH_3$, optionally substituted $-NH-(C_1-C_6)$alkyl, optionally substituted $-NH-(C_1-C_6)$alkyl-(C_1-C_6)alkoxy, optionally substituted $-SO_2-(C_1-C_6)$alkyl, optionally substituted $-SO_2-NH-(C_1-C_6)$alkyl, optionally substituted $-NH-SO_2-(C_1-C_6)$alkyl, optionally substituted 3- to 12-membered heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted – C_1-C_8-alkyl, optionally substituted – C_1-C_8-alkenyl, optionally substituted – C_3-C_8-cycloalkyl, optionally substituted – C_3-C_8-cycloalkenyl, and optionally substituted – C_1-C_8-alkoxy.


6. The compound of claim 1 wherein R_4 is substituted by one or two or three of the following substituents:

CH_3, CN, fluoro, chloro, CH_3O-, $CH_3C(O)$-, CH_3OCH_2-, $CH_3OCH_2CH_2O$-, -CF_3, CF_3O-,




and .


7. The compound of claim 1, represented by Formula **IIa-1**, **IIa-2**, **IIb-1**, or **IIb-2,**




(IIa-1)



(IIb-1)




(IIa-2)




(IIb-2)

or a pharmaceutically acceptable salt thereof, wherein R_2, R_3, R_4, R_5, R_6, n and A are as defined in claim 1.


8. The compound of claim 1, represented by Formula **IV-1**, **IV-2**, **IV-3**, or **IV-4,**




(IV-1)



(IV-2)




(IV-3)




(IV-4)

or a pharmaceutically acceptable salt thereof, wherein R_1, R_2, R_3, R_4, R_5, R_6, and n are as defined in claim 1.


9. The compound of claim 1, represented by Formula **V-1**, **V-2**, **V-3**, or **V-4**,




(V-1)



(V-2)




(V-4)




(V-3)

or a pharmaceutically acceptable salt thereof, wherein R_1, R_2, R_3, R_4, R_5, R_6, and n are as defined in claim 1.


10. The compound of claim 1, represented by one of Formulas (VIa-1) to (VIb-8),




(VIa-1)




(VIb-1)




(VIa-2)




(VIb-2)




(VIa-3)




(VIb-3)




(VIa-4)




(VIb-4)




(VIa-5)




(VIb-5)




(VIa-6)




(VIb-6)




(VIa-7)



(VIb-7)









(VIa-8)














































































(VIb-8)


































or a pharmaceutically acceptable salt thereof, wherein R_4 and R_6 are as defined in claim 1.

































11. The compound of claim 10 wherein R_4 is selected from the groups set forth in the table below, each of which is optionally substituted:









		
		









		
		
		
		
		
		
		
		
		
		
		

















		
		
		
		
		
		
		
		
		
		
		

















		
		
		

















.

















12. A compound selected from the compounds set forth below or a pharmaceutically acceptable salt thereof:

















Example	*Structure*	*Example*	Structure
1		2	
3		4	
5		6	
7a		7b	
















8		9	
10a		10b	
11		12	
13		14	
15		16	
17		19	
20		21	
22		23	















24		25	
26		27	
28		29	
30		31	
32		33	
34		35	
36		37	
38		39	















40		41	
42		43	
44		45	
46		47	
48		49	
50		51	
52		53	
54		55	















56		57	
58		59	
60		61	
62		63	
64		65	
66		67	
68		69	
70		71	















72		73	
74		75	
76		77	
80		81	
82		83	
84		85	
86		87	
88		89	















90		91	
92		93	
94		95	
96		97	
		107	
108		109	
110		111	
112		113	
















114		115	
116		117	
118		119	
120		121	
122		123	
124a		124b	
125a		125b	















126a		126b	
127		128	
129		130	
131		132	
133		134	
135		136	
137		138	















139		140	
141		142	
143		144	
145		146	
147		148	
149		150	
151		152	













153		154	
155		156	
157		158	
159		160	
161		162	
163		164	
165		166	













167		168	
169		170	
171		172	
173		174	
175		176	
177		178	
179		180	













181		182	
183		184	
185		186	
187			
195		196	
197		198	
199		200	
201		202	













		204	
205		206	
207		208	
209		210	
211		212	
		214	
215		216	
217		218	















219		220	
221		222	
223		224	
225		226	
227		228	
229		230	
231		232	













233		234	
235		236	
237		238	
239		240	
241		242	
243		244	













245		246	
247		248	
249		250	
251		252	
253		254	
255		256	













257		258	
259		260	
261		262	
263		264	
265		266	
267		268	















269		270	
271		272	
273		274	
275		276	
277		278	
279		280	















281		282	
283		284	
285		286	
287		288	
289		290	
291		292	
293		294	















295		296	
297		298	
299		300	
301		302	
303		304	
305		306	















307		308	
309		310	
311		312	
313		314	
315		316	
317		318	













319		320	
321		322	
323		324	
325		326	
327		328	
329		330	













331		332	
333		334	
335		336	
337		338	
339		340	
341		342	
343		344	













345		346	
347		348	
349		350	
351		352	
353		354	
355a		355b	
356		357	













358		359	
360		361	
362		363	
364		365	
366		367	
368		369	
370		371	













372		373	
374		375	
376		377	
378		379	
380		381	
382		383	
384		385	













386		387	
388		389	
390		391	
392		393	
394		395	
396		397	













398		399	
400		401	
402		403	
404		405	
406		407	
408		409	













410		411	
412	 412	413	 413
414		415	
416		417	
418		419	
420		421	













422		423	
424		425	
426		427	
428		429	
430		431	
432		433	













434		435	
436		437	
438		439	
440		441	
442		443	
444		445	













446		447	 447
448		449	
450		451	
452		453	
454		455	
456		457	


458		459	
460		461	
462		463	
464		465	
466		467	
468		469	

470		471	
472		473	
474		475	
476		477	
478		479	
480		481	


482		483	
484		485	
486		487	
488		489	
490		491	
492		493	

494		495	
496		497	
498		499	
500		501	
502		503	
504		505	

506		507	
508		509	
510		511	
512		513	
514		515	
516		517	


518			

13. The compound of claim 12 which is




or a pharmaceutically acceptable salt thereof.

14. The compound of claim 12 which is




or a pharmaceutically acceptable salt thereof.

15. The compound of claim 12 which is




or a pharmaceutically acceptable salt thereof.

16. The compound of claim 12 which is




or a pharmaceutically acceptable salt thereof.

17. The compound of claim 12 which is




or a pharmaceutically acceptable salt thereof.

18. The compound of claim 12 which is




or a pharmaceutically acceptable salt thereof.

19. The compound of claim 12 which is



or a pharmaceutically acceptable salt thereof.

20. The compound of claim 12 which is



or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, diluent or excipient.

22. A pharmaceutical composition comprising a compound according to any one of claims 13 to 20, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, diluent or excipient.

23. Use of a therapeutically effective amount of a compound according to any one of claims 1-12 in the manufacture of a medicament for the prevention or treatment of a respiratory syncytial virus infection.

24. Use of a therapeutically effective amount of a compound according to any one of claims 13-20 in the manufacture of a medicament for the prevention or treatment of a respiratory syncytial virus infection.